Anne DeGheest is managing partner at MedStars Ventures Partners. Since 1986, she pioneered the HealthTech or digital health space as a healthcare executive, an entrepreneur, angel investor, corporate advisor and mentor capitalist. She is the founder of MedStars and HealthTech Capital. The life science companies for which she has been a founder or an early advisor have generated over $9 billion in market capitalization including 8 IPOs. She provided angel capital, hands-on operating expertise and/or business strategy in the founding of major companies like Pyxis (CareFusion), Aspect Medical (acquired by Covidien), VISX (acquired by AMO), Thermage (merged into Solta Medical), VISICU(acquired by Philips), Masimo (Nasdaq: MASI).
She is a strategic advisor to larger corporations and has also helped grow new entrepreneurial division of large corporations like Johnson & Johnson, Baxter, Medtronic and McKesson.
She was part of the founding executive team of Nellcor (a division of Covidien), MedPool.com and OmniCell (Nasdaq: OMCL).
Anne founded in 2010 HealthTech Capital, a group of private investors dedicated to funding and mentoring new "HealthTech" start ups to decrease healthcare cost and empower patients. HealthTech capital is an ecosystem of angels, venture capitalists, providers and industry key players with the three sets of expertise needed to succeed in this new HealthTech space: healthcare, technology and user engagement.
She founded in 2012 the HealthTech conference, the leading conference on how to build new HealthTech Companies in the changing healthcare ecosystem. She is a frequent speaker and moderator at industry conferences. Anne is a guest-lecturer on entrepreneurship and angel investing at Stanford Business School, Dartmouth Tuck and Singularity University. She has extensive private and public board experience. She was an Entrepreneur-In-Residence with Canaan Partners and Institutional Venture partners. She started her career at Raychem after receiving a MBA from Harvard and a Master in Business Engineering from University of Brussels.
Bob Molinari specializes in biotechnology reagents, genomics, proteomics, and biopharmaceutical research companies. He is currently the founding CEO of Retrotope, Inc., focused on isotopic control of metabolic processes associated with diseases of oxidative stress. He was the founding CEO of Coda Genomics/Verdezyne, a computational proteomics company bringing the power of synthetic biology to industrial biosynthesis processes. В Bob is on the biotech screening committee of the Life Science Angels. He also serves on the boards of directors of early stage life science companies: Lypro Biosciences, Allylix Inc., and PharmaSecure, Inc. He is a Healthcare Horizons affiliate to the Institute for the Future, a Menlo Park-based think tank forecasting disruptive industry and social trends. Bob was also the co-founding CEO and president of Protogene Laboratories, Inc., and, in the mid-nineties, led that company to become the world's largest supplier of custom DNA before it was acquired by Life Technologies, Inc. He then ran a spin-off of Protogene which developed the first viable ink jet synthesis technology for custom DNA chips. Prior to Protogene, Bob served as a strategic advisor in the startup of Nanogen, Affymetrix, and Sequenom. Early in his career, Dr. Molinari served as the founding CEO of Avitech Diagnostics, a company with DNA sequencing and mutation detection technology (which became part of Variagenics, Inc.) and was a consultant specializing in biotechnology at McKinsey & Co. Dr. Molinari has an A.B. and an MBA from Dartmouth College and a Ph.D. in biophysical chemistry from Brown University.